Advertisement

Advertisement

2019 ASH Annual Meeting & Exposition

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chr...

Leukemia
Lymphoma

Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting pr...

Leukemia
Immunotherapy

Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting pr...

Leukemia

Expert Point of View: James N. Gerson, MD

James N. Gerson, MD, Assistant Professor of Medicine at Perelman School of Medicine, University of Pennsylvania, Philadelphia, commented on the implications of the findings from CAPTIVATE. “Upfront t...

Leukemia

Oral Regimen of Ibrutinib/Venetoclax Achieves High Rates of Undetectable Minimal Residual Disease in CLL

Updated results of the phase II CAPTIVATE trial continue to show high response rates as well as high rates of undetectable minimal residual disease (MRD) with ibrutinib plus venetoclax as front-line t...

Leukemia

Treating Patients With Chronic Lymphocytic Leukemia in 2020

With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malig...

Leukemia
Immunotherapy

Expert Point of View: Javier Pinilla-Ibarz, MD, PhD

Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzuma...

Leukemia
Immunotherapy

Acalabrutinib Plus Obinutuzumab Superior to Obinutuzumab Plus Chlorambucil as Front-Line Treatment of CLL

Ibrutinib was the first Bruton’s tyrosine kinase (BTK) inhibitor to dramatically transform the treatment of patients with chronic lymphocytic leukemia (CLL) and other hematologic malignancies. The sec...

Hematologic Malignancies

Updates in Hematopoietic Cell Transplantation

To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting pr...

Multiple Myeloma

Expert Point of View: Suzanne Lentzsch, MD, PhD

Suzanne Lentzsch, MD, PhD, Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University, offered her thoughts on venetoclax-based regimens, such as the one...

Multiple Myeloma

Venetoclax Plus Dexamethasone Shows Activity in t(11;14) Multiple Myeloma

In a phase I/II study of patients with advanced multiple myeloma and t(11;14) translocations, the combination of venetoclax and dexamethasone showed strong, durable activity, even in patients refracto...

Expert Point of View: Chetasi Talati, MD

Chetasi Talati, MD, Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center, Tampa, Florida, commented on the study by Borthakur et al. “[Core-binding factor] acute myeloi...

Leukemia

FLAG-GO Achieves Deeper Remission Than FLAG-IDA in Favorable-Risk AML

Gemtuzumab ozogamicin, once approved in 2000 for the treatment of acute myeloid leukemia (AML), was taken off the market in 2010 due to toxicity concerns. Idarubicin has been used in place of gemtuzum...

Immunotherapy

Expert Point of View: Basem M. William, MD, MRCP

Basem M. William, MD, MRCP, Director of the T-Cell Lymphoma Program and Cutaneous Lymphoma Multidisciplinary Clinic at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hos...

Immunotherapy

Strong Activity Shown for Lisocabtagene Maraleucel CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma

Another CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be poised to enter the marketplace for aggressive relapsed or refractory large B-cell lymphoma, based on a high rate of rapid ...

Leukemia
Lymphoma
Multiple Myeloma
Immunotherapy

Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma

The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and specia...

Immunotherapy
Leukemia

Expert Point of View: Javier Pinilla-Ibarz, MD, PhD

Javier Pinilla-Ibarz, MD, PhD, Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzumab v...

Immunotherapy
Leukemia

Pivotal Trial Evaluates Second-Generation BTK Inhibitor Alone and in Combination With Obinutuzumab for First-Line Treatment of CLL

The second-generation Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib, alone, or in combination with obinutuzumab significantly improved progression-free survival compared with a standard combi...

Leukemia

Bruton’s Tyrosine Kinase Inhibitor Yields High Overall Response Rates in del(17p) CLL and SLL

In findings of the SEQUOIA trial and updated results of the AU-003 trial,1,2 zanubrutinib, a Bruton’s tyrosine inhibitor (BTK), was shown to produce high overall response rates for patients with chron...

Immunotherapy
Multiple Myeloma

Expert Point of View: Thierry Facon, MD, and Michael Jain, MD, PhD

Thierry Facon, MD, of Lille University Hospital in France, and Michael Jain, MD, PhD, of Moffitt Cancer Center, Tampa, were interviewed by The ASCO Post on the second-generation chimeric antigen rec...

Immunotherapy
Multiple Myeloma

Next-Generation BCMA-Targeted CAR T-Cell Therapies for Relapsed or Refractory Multiple Myeloma Explored in Early-Phase Trials

Two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses for patients with relapsed or refractory multiple myeloma, as well as potentially less ...

Immunotherapy
Lymphoma

Combination Brentuximab Vedotin, Nivolumab Explored in First-Line, Salvage Therapies for Patients With Hodgkin Lymphoma

Two separate studies are investigating brentuximab vedotin plus nivolumab combination therapy for adults with Hodgkin lymphoma: one as first-line therapy and another as salvage therapy for relapsed/re...

Immunotherapy
Hematologic Malignancies

Early Data Suggest Efficacy of Innovative CAR NK-Cell Therapy for B-Cell Malignancies

FT596, a novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product, was as effective as existing CAR T-cell platforms in killing cancer cells in vivo, and the combination of F...

Immunotherapy
Lymphoma

Bispecific Antibody Shows Activity in Post–CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Mosunetuzumab, an ­investigational ­bispecific antibody, demonstrated activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed aft...

Immunotherapy
Leukemia

Expert Point of View: Howard J. Weinstein, MD, and Robert A. Brodsky, MD

Commenting on the Children’s Oncology Group AALL1331 study, Howard J. Weinstein, MD, Chief of Pediatric Hematology­Oncology at Massachusetts General Hospital for Children and Harvard Medical School i...

Immunotherapy
Leukemia

Blinatumomab Post-reinduction Consolidation Improves Event-Free, Overall Survival vs Chemotherapy in Young Patients With B-Cell ALL

Among children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (ALL), the bispecific T-cell engager blinatumomab improved event-free survival and overall survival, compared wit...

Immunotherapy
Lymphoma

Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD

Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus...

Immunotherapy
Lymphoma

Will Bispecific Antibodies Compete With CAR T-Cell Therapy in Lymphoma?

Are second-generation bispecific antibodies the next big thing in lymphoma? Studies of these drugs were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Expos...

Hematologic Malignancies
Leukemia
Multiple Myeloma
Lymphoma
Immunotherapy

Conference Highlights From the 2019 American Society of Hematology Annual Meeting & Exposition

More than 25,000 specialists in hematology from over 115 countries attended the 61st American Society of Hematology (ASH) Annual Meeting & Exposition held last December in Orlando. The conference ...

Lymphoma
Immunotherapy

Expert Point of View: Edmund K. Waller, MD, PhD

Edmund K. Waller, MD, PhD, Professor, Departments of Medicine, Pathology, and Hematology and Medical Oncology at Emory University School of Medicine and Medical Director, Center for Stem Cell Processi...

Lymphoma
Immunotherapy

Study Finds ‘Bridge’ to CAR T-Cell Therapy May Be Detrimental to Survival

The use of bridging therapy before treatment with axicabtagene ciloleucel was associated with worse overall survival in univariate, multivariate, and propensity score–matched analyses performed on dat...

Lymphoma
Immunotherapy
Geriatric Oncology
Cost of Care

Expert Point of View: Michael Jain, MD, PhD

Michael Jain, MD, PhD, Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, Tampa, Florida, commented on Dr. Kilgore’s findings. Dr. ...

Lymphoma
Immunotherapy
Geriatric Oncology
Cost of Care

Real-World Data for CAR T-Cell Therapy Show Benefit in Older Patients With Lymphoma, Lower Subsequent Health-Care Costs

Once considered highly experimental, chimeric antigen receptor (CAR) T-cell therapy is now an established third-line treatment option for B-cell lymphomas and leukemias. CAR T-cell therapy has saved t...

Leukemia
Lymphoma

Expert Point of View: Joshua Brody, MD

Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, New York, commented on where zanubrutinib might fit in once the drug is approved. “The ...

Leukemia
Lymphoma

Two Clinical Trials Show Zanubrutinib Achieves High Response Rates in del(17p) CLL and SLL

The Bruton’s tyrosine kinase inhibitor (BTK) zanubrutinib continues to achieve high overall response rates for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), ev...

Lymphoma
Immunotherapy

Expert Point of View: Basem M. William, MD, MRCP(UK), FACP

Basem M. William, MD, MRCP(UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center–Arthur G. ...

Lymphoma
Immunotherapy

CAR T-Cell Therapy Comes to Mantle Cell Lymphoma

Advanced mantle cell lymphoma appears to be a good target for chimeric antigen receptor (CAR) T-cell therapy. Treatment with KTE-X19, an anti-CD19 CAR T-cell product, led to unprecedented outcomes in ...

Leukemia

Yale Cancer Center Study Suggests New Approaches Needed to Manage Ibrutinib-Related Toxicities in Patients With CLL

New findings by Yale Cancer Center and Smilow Cancer Hospital researchers show that, as the use of ibrutinib increases in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients ...

Leukemia
Geriatric Oncology

Oral CC-486 Maintenance Therapy Extends Survival in Older Patients With AML

Use of CC-486—an investigational oral form of azacitidine—as maintenance therapy significantly improved overall survival and relapse-free survival in older patients with newly diagnosed acute myeloid ...

Immunotherapy
Lymphoma

Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma

The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classi...

Leukemia
Immunotherapy

Expert Point of View: Howard J. Weinstein, MD

Commenting on the blinatumomab study, Howard J. Weinstein, MD, Chief of Pediatric Hematology-Oncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These...

Leukemia

Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia

To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings ...

Immunotherapy
Leukemia

Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL

Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therap...

Multiple Myeloma

Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma

To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings ...

Hematologic Malignancies
Immunotherapy

Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies

A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies. This agent is designed to overcome several ...

Leukemia

Selected Abstracts From the 2019 ASH Annual Meeting & Exposition

To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings ...

Hematologic Malignancies
Symptom Management

Expert Point of View: Preet M. Chaudhary, MD, PhD

Preet M. Chaudhary, MD, PhD, of the University of Southern California (USC) Keck School of Medicine, Los Angeles, commented on the HOVON-96 trial for The ASCO Post. Dr. Chaudhary is Professor and Chie...

Hematologic Malignancies
Symptom Management

Improved Prevention of Graft-vs-Host Disease Reported With Posttransplant Cyclophosphamide

Following allogeneic hematopoietic stem cell transplantation, cyclophosphamide significantly reduced grades II to IV acute and chronic extensive graft-vs-host disease compared with conventional immuno...

Immunotherapy
Multiple Myeloma

Phase Ib/II Studies Explore Next-Generation BCMA-Targeted CAR T-Cell Therapies in Multiple Myeloma

In patients with relapsed or refractory multiple myeloma, two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses, with seemingly less cytokine...

multiple myeloma
immunotherapy

Saad Z. Usmani, MD, on Carfilzomib, Dexamethasone, and Daratumumab for Relapsed or Refractory Myeloma

Saad Z. Usmani, MD, of the Levine Cancer Institute, discusses phase III study findings suggesting that the combination of carfilzomib/dexamethasone/daratumumab represents an efficacious new regimen fo...

Advertisement

Advertisement



Advertisement